BNP Paribas Reduces Bristol Myers Squibb Stake

Institutional investor trims holdings in pharmaceutical company

Mar. 16, 2026 at 7:53am

Got story updates? Submit your updates here. ›

BNP Paribas, a major institutional investor, has reduced its stake in Bristol Myers Squibb Company (NYSE:BMY) by 42.8% during the third quarter, according to a recent SEC filing. The fund now owns 36,085 shares of the biopharmaceutical company's stock, down from 63,118 shares previously.

Why it matters

This move by a prominent institutional investor like BNP Paribas could signal a shift in sentiment around Bristol Myers Squibb, which has seen its stock price fluctuate in recent quarters. The company's performance and pipeline will likely be closely watched by the investment community.

The details

According to the SEC filing, BNP Paribas sold 27,033 shares of Bristol Myers Squibb during the third quarter, reducing its total holdings to 36,085 shares. The fund's stake in the company was valued at $1.627 million as of the most recent filing.

  • BNP Paribas trimmed its Bristol Myers Squibb holdings during the third quarter of 2026.

The players

BNP Paribas

A major global financial institution and one of the world's largest investment management firms.

Bristol Myers Squibb Company

A leading biopharmaceutical company focused on developing and delivering innovative medicines for serious diseases.

Got photos? Submit your photos here. ›

The takeaway

The reduction in BNP Paribas' Bristol Myers Squibb stake suggests the investment firm may have concerns about the pharmaceutical company's near-term prospects, though the overall investment community remains divided on the stock's outlook.